Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27851979)
Watch
English
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
scientific article
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
23213094
retrieved
13 November 2016
title
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
(English)
1 reference
stated in
PubMed
PubMed ID
23213094
retrieved
13 November 2016
main subject
biomarker
0 references
patient
0 references
renal cell carcinoma
1 reference
based on heuristic
inferred from title
author
Keith Flaherty
series ordinal
16
object named as
Keith T Flaherty
0 references
Toni K Choueiri
series ordinal
1
object named as
Toni K Choueiri
0 references
author name string
Ulka Vaishampayan
series ordinal
2
0 references
Jonathan E Rosenberg
series ordinal
3
0 references
Theodore F Logan
series ordinal
4
0 references
Andrea L Harzstark
series ordinal
5
0 references
Ronald M Bukowski
series ordinal
6
0 references
Brian I Rini
series ordinal
7
0 references
Sandy Srinivas
series ordinal
8
0 references
Mark N Stein
series ordinal
9
0 references
Laurel M Adams
series ordinal
10
0 references
Lone H Ottesen
series ordinal
11
0 references
Kevin H Laubscher
series ordinal
12
0 references
Laurie Sherman
series ordinal
13
0 references
David F McDermott
series ordinal
14
0 references
Naomi B Haas
series ordinal
15
0 references
Robert Ross
series ordinal
17
0 references
Peter Eisenberg
series ordinal
18
0 references
Paul S Meltzer
series ordinal
19
0 references
Maria J Merino
series ordinal
20
0 references
Donald P Bottaro
series ordinal
21
0 references
W Marston Linehan
series ordinal
22
0 references
Ramaprasad Srinivasan
series ordinal
23
0 references
language of work or name
English
0 references
publication date
10 January 2013
0 references
published in
Journal of Clinical Oncology
0 references
volume
31
0 references
issue
2
0 references
page(s)
181-6
0 references
cites work
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
20 March 2017
Cancer statistics, 2010
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
20 March 2017
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
20 March 2017
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
29 September 2017
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
29 September 2017
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
29 September 2017
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
29 September 2017
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
29 September 2017
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
29 September 2017
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
29 September 2017
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
29 September 2017
Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
2 June 2018
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
2 June 2018
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
27 November 2018
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
27 November 2018
Declaration of Helsinki. Ethical principles for medical research involving human subjects.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
27 November 2018
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
27 November 2018
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3532390
retrieved
27 November 2018
Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23213094
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Papillary renal tumors. Morphologic, cytochemical, and genotypic features
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23213094
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23213094
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1200/JCO.2012.43.3383
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3362164
OpenCitations bibliographic resource ID
3362164
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3362164
PMCID
3532390
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3362164
PubMed ID
23213094
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3362164
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
